BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peiffer-Smadja N, Bridier-Nahmias A, Ferré VM, Charpentier C, Garé M, Rioux C, Allemand A, Lavallée P, Ghosn J, Kramer L, Descamps D, Yazdanpanah Y, Visseaux B. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses 2021;13:1642. [PMID: 34452507 DOI: 10.3390/v13081642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Ferré VM, Peiffer-Smadja N, Kramer L, Coppée R, Kante A, Debarge M, Choquet C, Saint Joannis T, Bouzid D, Messika J, Le Grand J, Thy M, Kernéis S, Descamps D, Visseaux B, Ghosn J. Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy. Microbiol Spectr 2022;:e0215222. [PMID: 36125289 DOI: 10.1128/spectrum.02152-22] [Reference Citation Analysis]
2 Del Bello A, Marion O, Izopet J, Kamar N. Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients? Viruses 2022;14:1860. [DOI: 10.3390/v14091860] [Reference Citation Analysis]
3 Simons LM, Ozer EA, Gambut S, Dean TJ, Zhang L, Bhimalli P, Schneider JR, Mamede JI, Ison MG, Karmali R, Gordon LI, Lorenzo-Redondo R, Hultquist JF. De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients. Transpl Infect Dis 2022;:e13914. [PMID: 35899968 DOI: 10.1111/tid.13914] [Reference Citation Analysis]
4 Mizrahi RA, Lin WY, Gras A, Niedecken AR, Wagner EK, Keating SM, Ikon N, Manickam VA, Asensio MA, Leong J, Medina-cucurella AV, Benzie E, Carter KP, Chiang Y, Edgar RC, Leong R, Lim YW, Simons JF, Spindler MJ, Stadtmiller K, Wayham N, Büscher D, Terencio JV, Germanio CD, Chamow SM, Olson C, Pino PA, Park J, Hicks A, Ye C, Garcia-vilanova A, Martinez-sobrido L, Torrelles JB, Johnson DS, Adler AS. GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2. Pathogens 2022;11:806. [DOI: 10.3390/pathogens11070806] [Reference Citation Analysis]
5 Eweas AF, Osman HH, Naguib IA, Abourehab MAS, Abdel-Moneim AS. Virtual Screening of Repurposed Drugs as Potential Spike Protein Inhibitors of Different SARS-CoV-2 Variants: Molecular Docking Study. Curr Issues Mol Biol 2022;44:3018-29. [PMID: 35877432 DOI: 10.3390/cimb44070208] [Reference Citation Analysis]
6 Markarian NM, Galli G, Patel D, Hemmings M, Nagpal P, Berghuis AM, Abrahamyan L, Vidal SM. Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency. Front Microbiol 2022;13:933983. [DOI: 10.3389/fmicb.2022.933983] [Reference Citation Analysis]
7 Candido KL, Eich CR, de Fariña LO, Kadowaki MK, da Conceição Silva JL, Maller A, Simão RCG. Spike protein of SARS-CoV-2 variants: a brief review and practical implications. Braz J Microbiol 2022. [PMID: 35397075 DOI: 10.1007/s42770-022-00743-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 van der Straten K, van Gils MJ, de Taeye SW, de Bree GJ. Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation. Front Med Technol 2022;4:867982. [DOI: 10.3389/fmedt.2022.867982] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Flores-Vega VR, Monroy-Molina JV, Jiménez-Hernández LE, Torres AG, Santos-Preciado JI, Rosales-Reyes R. SARS-CoV-2: Evolution and Emergence of New Viral Variants. Viruses 2022;14:653. [PMID: 35458383 DOI: 10.3390/v14040653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Ameratunga R, Woon S, Lea E, Steele R, Lehnert K, Leung E, Brooks AES. The (apparent) antibody paradox in COVID-19. Expert Review of Clinical Immunology. [DOI: 10.1080/1744666x.2022.2044797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Liu H, Wei P, Kappler JW, Marrack P, Zhang G. SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity. Front Immunol 2022;13:825256. [PMID: 35154144 DOI: 10.3389/fimmu.2022.825256] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
12 Focosi D, Maggi F, McConnell S, Casadevall A. Spike mutations in SARS-CoV-2 AY sublineages of the Delta variant of concern: implications for the future of the pandemic. Future Microbiol 2022. [PMID: 35164530 DOI: 10.2217/fmb-2021-0286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kovacech B, Fialova L, Filipcik P, Skrabana R, Zilkova M, Paulenka-Ivanovova N, Kovac A, Palova D, Rolkova GP, Tomkova K, Csokova NT, Markova K, Skrabanova M, Sinska K, Basheer N, Majerova P, Hanes J, Parrak V, Prcina M, Cehlar O, Cente M, Piestansky J, Fresser M, Novak M, Slavikova M, Borsova K, Cabanova V, Brejova B, Vinař T, Nosek J, Klempa B, Eyer L, Hönig V, Palus M, Ruzek D, Vyhlidalova T, Strakova P, Mrazkova B, Zudova D, Koubkova G, Novosadova V, Prochazka J, Sedlacek R, Zilka N, Kontsekova E. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. EBioMedicine 2022;76:103818. [PMID: 35078012 DOI: 10.1016/j.ebiom.2022.103818] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Sabin AP, Richmond CS, Kenny PA. Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient. Diagnostic Microbiology and Infectious Disease 2022. [DOI: 10.1016/j.diagmicrobio.2022.115656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. Int J Mol Sci 2021;23:29. [PMID: 35008446 DOI: 10.3390/ijms23010029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
16 Bronstein Y, Adler A, Katash H, Halutz O, Herishanu Y, Levytskyi K. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection. J Med Virol 2021. [PMID: 34755363 DOI: 10.1002/jmv.27445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Lundstrom K, Aljabali AAA. COVID-19 in 2021. Viruses 2021;13:2098. [PMID: 34696528 DOI: 10.3390/v13102098] [Reference Citation Analysis]